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compressed matrix tablets, affects the characteristics of the formed tablets. Three polymers of differ-
ent deformation mechanisms were tested for their impact on theophylline directly compressed tablets
namely Kollidon SR (KL SR, plastic deformation), Ethylcellulose (EC, elastic deformation) and
Carnauba wax (CW, brittle deformation) at different compression forces. However, tablets based
mainly onKL SR, the plastically deformed polymer (TN1) exhibited the highest hardness values com-
pared to the other formulae which are based on either blends of KL SR with CW, the very brittle
deformed polymer. The upper detected force for TN formulae and the lower punch force were found
to dependentmainly on the powder deformation. This difference is attributed to the work done during
the compression phase as well as the work lost during the decompression phase. Furthermore, the
release proﬁles of TN from formulae TN2 and TN4 that are based on the composition (2KL SR:1EC)
and (1KL SR:2EC), respectively, were consistent with different deformation mechanisms of KL SR(I. El-Bagory).
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230 I. El-Bagory et al.andECandon the physicochemical properties like thewater absorptive capacity ofEC.Upon increas-
ing the weight ratio of KL SR (TN2), the release rate was greatly retarded (39.4%, 37.1%, 35.0% and
33.6% released after 8 h at 5, 10, 15 and 20 kN.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The mechanism of powder compaction not only depends on the
powder properties (Jones, 1977) but also affected by particle
size, shape (Wong and Pilpel, 1990), moister content (Sebhatu
et al., 1997; Bell and Labuza, 2000) and experimental condi-
tions, e.g. applied pressure (Holman and Leuenberger, 1988)
and velocity of compaction (Roberts and Rowe, 1985). In addi-
tion, the properties of the resulting compact can be inﬂuenced
by the presence of a lubricant and binder (Nystrom et al.,
1982), since pharmaceutical materials normally consolidate
by more than one of the mechanisms (Duberg and Nystrom,
1986), adequate characterization techniques are needed. Vari-
ous techniques have been utilized to determine the extent of
consolidation and bonding mechanisms in pharmaceutical
powders (Luangtana-Anan and Fell, 1990; Karehill et al.,
1990), such as stress relief under pressure (Rees and Rue,
1978), X-ray diffraction (Munoz-Ruiz et al., 1996) and multi-
compression cycle (Khossravi and Morehead, 1997).
There exists no pharmaceutical powder that exhibits only
one of the above mentioned deformation mechanisms,
although there is a spectrum of ranges from highly elastically
deforming to highly plastically deforming or highly brittle
materials. Even for materials that are known to be brittle, smal-
ler particles may deform plastically (Amidon, 1989). A prere-
quisite for the formation of a coherent compact is that the
surfaces deform to such an extent that the combined effects
of bonding with intermolecular forces and solid bridges are
greater than the elastic component of the material. This can
be expressed as the critical compaction pressure needed to form
a compact (Karehill et al., 1990).
The frequency of defects in crystalline solids can be related
to deformation during compression (Huttenrauch, 1977). The
change can take place in crystal structure and shape. Such
structural changes are opposed by intermolecular forces which
restore the crystal to its original form, as in the case of elastic
materials. If the intermolecular forces are exceeded, plastic or
permanent deformation will result and, if the stress is contin-
ued, plastic ﬂow will continue (Hess, 1978).
Polymer blending is an alternative approach to obtain new
materials with desirable properties based on commercially
available polymers rather than to design and synthesize com-
pletely new polymers. Polymer blending is designed to generate
materials with optimized chemical, structural, mechanical,
morphological and biological properties (Calvert et al., 2000;
Meredith et al., 2003; Lua et al., 2007). The use of polymers
as release rate modiﬁers has become an important area of drug
development work. Over the years, the use of polymers and
other materials to prolong the drug release rate has become
more popular. The use of polymer combinations is an
approach that may allow formulators to develop sustained
release drug dosage forms that may show performance
improvements over the individual polymer components.Polymer blending provides a neat and smooth means of com-
bining desirable properties of different polymers. Biodegrad-
able matrices with new combinations of polymer properties
and modiﬁcation of drug release proﬁles can thus be obtained
(Domb, 1990; Illum, 1998).
Theophylline (TN) structurally classiﬁed as methyl xanthine
is widely used as a bronchodilator in patients with airﬂow lim-
itation diseases such as bronchial asthma and chronic obstruc-
tive pulmonary disease (COPD) Yoon et al., 2008.
Theophylline is rapidly and completely absorbed from liquid
preparation, capsules and uncoated tablets. The rate, but not
the extent, of absorption is decreased by food. Theophylline
is approximately 40% bound to plasma proteins, but in
neonates, or adults with liver disease, binding is reduced
(Reynolds, 1993). There are marked variations in TN pharma-
cokinetics with plasma half-lives ranging from 3 to 9 h.
The objective of this study was to formulate sustained re-
lease of TN tablets by direct compression of the tablets with
four different compression forces using different polymer
blends. Tablets were evaluated for their strength, uniformity
of thickness, friability, in addition to their mechanical behav-
ior as hardness, upper and lower compression force, ejection
force and tensile strength. Moreover, the in vitro release pat-
terns of TN from the formulated tablets were studied over
the sustained release period.2. Methodology
2.1. Materials
Anhydrous theophylline (TN) and Carnauba wax (CW) were
kindly supplied from Tabuk Pharmaceutical Manufacturing
CO, KSA. Ethylcellulose, EC (having a dynamic viscosity of
14 cp for 5% solution in toluene 80 : ethanol 20), was purchased
from BDH Laboratory Supplies Poole, England. Kollidon SR
(KL SR) was obtained from BASF Aktiengesellschaft, Ger-
many.Magnesium stearate and hydrochloric acidwere obtained
from Riedel-de-Haen, AG, Germany, tribasicphosphate octa-
hydrate (Scharlau Chemies.A, European). All other materials
and solvents used are of reagent or analytical grade and they
were used without further puriﬁcation.
2.2. Formulation of directly compressed tablets
The compositions of the prepared direct compressed tablets
containing TN are shown in Table 1. Each tablet contains
50 mg drug and uses one polymer or blend of the polymer
KL SR, EC and CW in different ratios. The powders of all
ingredients were passed separately through a sieve of 250 lm
opening size and the powders were then thoroughly mixed
using turbula mixer for 15 min. The powder then compresses
into tablets by using Flexitap single punch machine (IWKA
Table 1 Amount of ingredient in each formulation in mg for Theophylline tablet, total weight of one tablet = 201 mg containing
50 mg drug.
Code Kollidon SR Carnauba wax Ethylcellulose Magnesium stearate
TN1 150 – – 1
TN2 100 – 50 1
TN3 100 50 – 1
TN4 50 – 100 1
TN5 50 100 – 1
TN6 – 75 75 1
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15 and 20 kN. In another study, the powder also compresses
into tablets using Korsch single punch tablet press (EKO,
K3300079, Germany) by ﬁxing tablet weight and measuring
the maximum compression forces.
2.3. Characterization of tablets
2.3.1. Tablets weight uniformity
The tablets weight uniformity test was carried out according to
USP 29. Ten tablets were weighed individually. The results
were expressed as mean value of 10 determinations.
2.3.2. Drug content uniformity
The content uniformity was assessed according to USP
requirements for content uniformity. The test is used to ensure
that every tablet contains the amount of drug substance in-
tended with a negligible variation among tablets within a
batch. Ten tablets from each formulation were tested. Each
tablet was weighed individually and crushed to a powder. An
accurately weighed sample (100 mg) was placed in a 50 mL
volumetric ﬂask and the drug was extracted by distilled water.
The content of the ﬂask was sonicated for 20 min at room tem-
perature. Five milliliters aliquot was ﬁltered through 0.45 lm
ﬁlter, suitably diluted and analyzed spectrophotometrically at
kmax of 271 nm.
2.3.3. Tablet thickness
The thickness of theophylline matrix tablets with the tested
polymers or polymers blends was determined using a microm-
eter (Type TB-24, Erweka Apparatebau, Heusenstamm,
Germany) and the result was expressed as mean values of 10
determinations.
2.3.4. Tablet friability
Ten tablets were selected at random; their surfaces cleaned
with a hair brush to remove any adhering dust, weighed and
placed in the friabilator (Type TA3R, Erweka Apparatebau,
Heusenstamm, Germany). They were then allowed to fall
freely 100 times from a height of 6 inch at a speed of 25 rpm
for 4 min. The tablets were then dusted, and weighed. Any loss
in weight due to fracture or abrasion was recorded as a per-
centage weight loss. The replicate determinations of each for-
mulation were averaged. The percent friability was calculated
as follow:
%Friability ¼ ½ðinitial weight final weightÞ=initial weight
 1002.3.5. Tablet hardness
The hardness of theophylline loaded matrix tablets was deter-
mined using Pharmatest Test System (WHT 32.V02.09.00/15,
Multicheck, Germany) and the average hardness of 10 deter-
minations in Newton (N) was determined.
2.3.6. Tensile strength determination
The determination of the tensile strength of the tablet depends
on the development of a correct state of stress within the com-
pact (Fell and Newton, 1970), but is less dependent on the
compact geometry than the crushing strength measurements.
The radial tensile strength, which measures the tablet failure
as a result of the application of tensile stress only, is given
by the relationship:
rx ¼ 2F=pDT
where rx is the tensile strength, F is the force required to break
the tablet, D is the diameter of the tablet, and T is the tablet
thickness.
2.4. In-vitro release studies
In vitro drug release studies from the prepared tablets were
conducted according to the method described by Fayed et al.
(2011) for a period of 8 h using a six station USP 28 type II
apparatus (paddle) at 37 ± 0.5C and 50 rpm speed (dissolu-
tion apparatus (Erweka DT-6, Germany)). The dissolution
studies were carried out in triplicate for 8 h (initial 2 h use
750 mL 0.1 N HCl, and the rest 6 h add 250 mL 0.2 M tribasic-
sodium phosphate octahydrate PH 7.4) under sink condition,
at every 1 h interval samples of 5 mL were withdrawn from
the dissolution medium and replaced with fresh medium to
maintain the volume constant. After ﬁltration and appropriate
dilution, the sample solution was analyzed by UV spectropho-
tometer. The amounts of drug present in the samples were
calculated with the help of appropriate calibration curves.
Drug dissolved at speciﬁed time periods was plotted as percent
release versus time curve.
2.5. Mathematical modeling of release kinetics
The in vitro release of drug from different tablets formulations
was evaluated by ﬁtting the dissolution data obtained to the
following equations.
2.5.1. Zero order equation
Ct ¼ C0  K0t
232 I. El-Bagory et al.where Ct is the amount of the drug released at time t, C0 is the
initial amount of drug in the tablet and K0 is the zero-order
release rate constant.2.5.2. First order equation
LogCt ¼ LogC0  K1t=2:303
where Ct is the amount of drug remaining as a solid state at
time t, C0 is the total amount of drug in the matrix and K1
is the ﬁrst-order release rate constant.
2.5.3. Higuchi model equation
Q ¼ 2CoðDt=pÞ1=2
whereCo is the initial drug concentration, t is time of release, Q
is the amount of drug released/unit area and D is the diffusion
coefﬁcient and it was calculated according to the following
equation (Higuchi, 1963).
D ¼ ðSlope=2CoÞ2p2.5.4. Korsmeyer–Peppas equation
Mt=M1 ¼ K  tn
whereMt/M1 is the fraction released by the drug at time t, K
is a constant incorporating structural and geometric character-
istic and n is the release exponent characteristic for the drug
transport mechanism.
2.6. Statistical analysis
All results were expressed as mean values ± standard deviation
(SD). The determined dissolution data was subjected to statisti-
cal analysis using a computer program, Graphpad INSTAT tm
Copyrightª 1990-1993 (Version 2.04, Ralf Stahlman, Purdue
University, USA, 931897S) for a one-way analysis of variance
(ANOVA).P< 0.05 was considered as evidence of a signiﬁcant
difference.3. Results and discussion
3.1. Tablet evaluation
3.1.1. Physical evaluation of tablets
Tablets containing TN manufactured by direct compression at
different polymer blends and at different compression forces,
viz., 5, 10, 15 and 20 kN, were evaluated and the data are pre-
sented in Tables 2A and 2B. It was clear that the manufactured
tablets exhibit acceptable properties in terms of weight unifor-
mity, diameter, thickness, hardness, friability and die ﬁlling at
the studied compression forces. For all the compression forces
used, the weight variation was under 4%. The variation of
diameter and thickness was un-existing as can be seen in the
table. Hardness is obviously a parameter which can be related
directly to the compression force used. However, tablets based
mainly on KL SR, the plastically deformed polymer (TN1)
exhibited the highest hardness values compared to the other
formulae which are based on either blends of KL SR withCW, the very brittle deformed polymer as the tablet formulae
TN3 and TN5, or EC, the elastically deformed polymer as the
case of TN2 and TN4 formulations or on blend of EC and CW
(TN6), which showed lower hardness values. This ﬁnding is
matched with the reported data that show that direct compres-
sion using KL SR resulted in tablets with an extremely high
hardness and a low friability (Reza et al., 2002). According
to the chemical composition and the adjusted particle size dis-
tribution, the marked dry binding capacity in combination
with the good ﬂow properties, are regarded as additional ben-
eﬁts (Reza et al., 2002; Shao et al., 2001). Another ﬁnding that
the increase in hardness upon increasing the compression force
was also higher and remarkable in the case of KL SR TN1
compared to the rest of formulae, Fig. 1A. The friability of
the tablets behaved normally and quite expectedly (Fig. 1B).
Within the compression force region 5–20 kN the friability of
the tablets was 0.0 in case of the KL SR based tablets TN1,
while decreased with increasing the compression force for the
other formulae and that was clearly evident in the TN6 formu-
lae, where it decreases from 0.05%, 0.03%, 0.015% and
0.0075% at 5, 10, 15 and 20 kN compression forces respec-
tively. In this work, the friability of the tablets behaves as ex-
pected at lower compression force. When the compression
force increases, the particles deform plastically and the tablets
become harder and less friable. However, the recorded friabil-
ity values for TN formulae were under 1% which can generally
be regarded as desirable.
The physical strength of a tablet is also dependent on its
dimension. In the construction of a force strength proﬁle, all
tablets will have the same cross-sectional area as the same tool-
ing will have been used. However, as the compression force is
changed, so will the tablet height. Hence, comparison made on
the basis of breaking strength will not be truly valid. This
problem has been circumvented in part by the calculation of
the tensile strength of the tablet. Tensile strength data pre-
sented in Tables 2A and 2B illustrated how the tensile strength
is correlated to the tablet hardness and how both the tablet
hardness and the tablet tensile strength been affected at the
same manner with the compression force (Fig. 1C) and defor-
mation mechanism of the used material. Formula TN1, the
highest hardness value showed, the highest value of tensile
strength and that tensile strength value increases as the com-
pression force. These tensile strength observations are matched
with the report by Riikka et al. (2006), that the higher the
porosity and dissolution rate, the smaller the tensile strength.
3.1.2. Machine mechanical behavior
The aim of any tabletting process is to produce tablets that are
of satisfactory quality. Virtually all tablet properties e.g.,
porosity, physical strength, dissolution time are dependent in
some way on the force that is applied by the punches to the
particles in the die. As the upper punch enters the die and
comes into contact with the particles, the height of the bed
of particles is reduced and hence porosity decreases. Initially
porosity reduction is brought about by particle rearrangement.
This requires a very low force transducer, the output of which
remains zero. The upper punch then encounters a resistance to
its motion as further consolidation by rearrangement becomes
impossible. Hence, the output of the upper punch force trans-
ducer rises, slowly at ﬁrst then more rapidly. Particles are de-
formed and/or fragmented during this stage to form a
Table 2B Physical characterization of matrix tablets of theophylline compressed at 15 and 20 kN.
Formulation Weight (mg)
n= 10
Diameter (mm)
n= 10
Thickness (mm)
n= 10
Hardness (N)
n= 10
Friability (%)
n= 10
Tensile strength
(N/cm2) n= 5
Die ﬁlling
C. Compression force 15 kN
TN1 0.2 ± 203 8.7 4.5 362.9 ± 2.3 0 590.4 ± 2 6.9
TN2 1.1 ± 194 8.7 4.5 266.1 ± 4 0 432.9 ± 1.1 6.9
TN3 0.42 ± 199 8.7 4.5 189.5 ± 2.2 0 308.3 ± 2.1 6.8
TN4 0.04 ± 203 8.7 4.5 202.9 ± 3.5 0 330 ± 2.6 7.2
TN5 1.0 ± 200 8.7 4.5 106.7 ± 1.15 0.02 173.9 ± 1.9 6.6
TN6 0.03 ± 201 8.7 4.5 88 ± 0.85 0.01 144.5 ± 1.1 6.6
D. Compression force 20 kN
TN1 1.4 ± 203 8.7 4.5 399.2 ± 10.2 0 649.5 ± 10.1 6.8
TN2 1.2 ± 198 8.7 4.5 293.1 ± 4.7 0 476.85 ± 3.1 6.9
TN3 1.3 ± 198 8.7 4.5 1.7 ± 195.6 0.01 318.2 ± 1.18 6.8
TN4 1.1 ± 201 8.7 4.5 210.3 ± 2.1 0 342.1 ± 3.15 7.2
TN5 1.1 ± 199 8.7 4.5 0.9 ± 109.4 0.04 177.98 ± 1.4 6.6
TN6 1.4 ± 200 8.7 4.5 85.3 ± 1 0.02 138.7 ± 2.3 6.6
Table 2A Physical characterization of matrix tablets of theophylline compressed at 5 and 10 kN.
Formulation Weight (mg)
n= 10
Diameter (mm)
n= 10
Thickness (mm)
n= 10
Hardness (N)
n= 10
Friability (%)
n= 10
Tensile strength (N/cm2)
n= 10
Die ﬁlling
A. Compression force 5 kN
TN1 1.3 ± 199 8.7 4.5 243.2 ± 12 0 395.6 ± 10 6.8
TN2 0.5 ± 201 8.7 4.5 162.9 ± 6 0 265.1 ± 4.0 6.9
TN3 1.4 ± 199 8.7 4.5 138.1 ± 2 0.01 224.5 ± 2.1 6.8
TN4 1.1 ± 199 8.7 4.5 102.4 ± 83 0 165.9 ± 3.0 7.2
TN5 1.0 ± 200 8.7 4.5 87.1 ± 1.1 0.01 141.7 ± 2.2 6.6
TN6 1.0 ± 203 8.7 4.5 57.6 ± 1.05 0.02 93.79 ± 0.5 6.6
B. Compression force 10 kN
TN1 1.5 ± 196 8.7 4.5 360 ± 12.4 0 586.7 ± 8.4 6.9
TN2 0.5 ± 199 8.7 4.5 246.8 ± 4.3 0 401.5 ± 3 6.9
TN3 0.25 ± 200 8.7 4.5 180.5 ± 2.5 0.01 293.6 ± 2.2 6.8
TN4 0.45 ± 200 8.7 4.5 170.3 ± 3.4 0 2.6 ± 277 7.2
TN5 1.0 ± 201 8.7 4.5 104.6 ± 0.9 0.01 170.2 ± 1 6.6
TN6 0.21 ± 203 8.7 4.5 81 ± 0.93 0.01 133 ± 0.87 6.6
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similar rise is detected by transducer there. As maximum upper
punch penetration is achieved, force maximum is detected on
both punches that on the lower punch being less than that
on the upper. Once the maximum has occurred, the upper
punch begins to rise, and the force detected on both punches
falls. The upper punch returns to zero as contact is lost be-
tween the ascending punch and the top surface of the tablet.
That on the lower punch does not fall to zero until ejection
is complete. The greater the ejection force, the greater the need
for a lubrication in the formulation.
The reason why the lower punch maximum force is less
than that of the upper punch is because a fraction of the force
applied by the upper punch is transmitted to the die wall and
the deformation mechanism. That the elastic deformation is a
spontaneous reversible deformation in which, upon removal of
the load, the powder mass reverts back to its original form.
After exceeding the elastic limit of the material, the deforma-
tion may become plastic, that is, the particles undergo viscous
ﬂow. This is the predominant mechanism where the shear
strength between the particles is less than the tensile or break-
ing strength. Upon exceeding the elastic limit of material, the
particles undergo brittle fracture if the shear strength betweenthe particles is greater than the tensile or breaking strength.
Table 3 illustrated the direct compression mechanical parame-
ters released from TN formulations based on the deformation
mechanism. When the polymer used was mainly plastically
deformed KL SR, the upper detected force for formulae
TN1 was 8.18 kN where the lower punch force was 7.45 and
the difference between the upper and lower forces (U–L) was
0.73 kN and the ejection force was 33.94 N. While changing
the deformation type from a mainly plastic deformation mech-
anism to a blend composed of (2KL SR:1EC) plastic:elastic
(TN2), the detected upper punch force was 8.46 kN and the
lower force was 7.63 kN and the U–L was 0.83 and the ejection
force was 29.74 N. This difference is attributed to the work
done during the compression phase as well as the work lost
during the decompression phase.
3.1.3. Content uniformity
Theophylline content in all of the tested tablet formulations
was found to be more than 95% which meets the USP guide-
lines even when different compression forces were applied. In
addition, it is observed that the type and ratio of the matrix
forming polymers as well as the compression force have no im-
pact on the TN content.
Figure 1 Relation between compression force and each of (A) hardness, (B) friability, and (C) tensile strength for theophylline
formulation compressed at 5, 10, 15 and 20 kN.
Table 3 Direct compression mechanical parameters released from theophylline formulations using Korsch single punch tablet press.
Formula Compressibility
index
Upper punch
compression
force (U) (kN)
Lower punch
compression
force (L) (kN)
U–L* (kN) Ejection Force (N) Deformation
mechanism
TN1 23.42 8.18 7.45 0.73 33.94 Plastic
TN2 20 8.46 7.63 0.82 29.74 Plastic:elastic(2:1)
TN3 24.33 7.28 6.63 0.65 29.56 Plastic:brittle(2:1)
TN4 33.3 4.94 4.53 0.41 25.86 Plastic:elastic(1:2)
TN5 25.1 8.85 8.75 0.1 25.84 Plastic:brittle(1:2)
TN6 31.34 8.85 8.75 0.1 26.38 Elastic:brittle(1:1)
* Upper punch–Lower punch
234 I. El-Bagory et al.3.2. In-vitro release proﬁles
The in vitro release patterns of TN from different matrix tablet
formulations compressed at different compression forces (5,
10, 15 and 20 kN) are presented in Figs. 2–5. For all studied
compression forces, the matrix tablet formulation includingKL SR, the plastic polymer with reduced repacking during
deformation, in combination with either CW or EC showed
very interesting TN release proﬁles. The release proﬁles of
TN from formulae TN2 and TN4 that are based on the com-
position (2KL SR:1EC) and (1KL SR:2EC), respectively, were
consistent with different deformation mechanisms of KL SR
Figure 2 Release proﬁle of theophylline from tablet compressed
at 5 and 10 kN.
Figure 3 Release proﬁle of theophylline from tablet compressed
at 15 and 20 kN
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Figure 4 Release proﬁle of theophylline from formulations TN1,
TN2, and TN3.
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absorptive capacity of EC. Upon increasing the weight ratio
of KL SR (TN2), the release rate was greatly retarded
(39.4%, 37.1%, 35.0% and 33.6% released after 8 h at 5, 10,
15 and 20 kN) Fig. 4, while formulae TN4 released TN more
faster (45%, 43.1%, 42.3% and 41.2% released after 8 h at
5, 10, 15 and 20 kN). In fact, the water absorptive property
of EC has the most prominent impact on the drug release when
compared to the reduced repacking of KL SR.
On the other hand, the release proﬁles of TN from formulae
TN3 and TN5 that are based on the composition (2KL
SR:1CW) and (1KL SR:2CW), respectively, were also consis-
tent with different deformation mechanisms of KL SR and
CW. By increasing the weight ratio of KL SR (TN3), the
release rate was remarkably enhanced (32%, 33.6%, 35.6%
and 40.7% released after 8 h at 5, 10, 15 and 20 kN), while for-
mulae TN5 released TN more retarded (43%, 43.8%, 45% and
45.5% released after 8 h at 5, 10, 15 and 20 kN) Fig. 5. The
brittle deformation mechanism of CW plays an important role
in increasing TN release (Huang et al., 2006). This was very
clear in formulae TN5, where the weight ratio of CW was dou-
ble increased. The effect of compression force on the in vitro
release rate of TN from each formula was studied and the
results were illustrated in Figs. 4 and 5. The formulae based
on Kollidon only or a combination of Kollidon SR 2:1EC
(TN1 and TN3, respectively) showed that a higher release rate
was observed at a compression force of 20 kN. On the other
hand, formulae TN2, TN4 and TN6 showed that the release
rate of the drug from the matrix tablet formulae is inversely
proportional to the applied compression force, Figs. 4 and 5.
The effect of the compression force on the in vitro release pat-
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Figure 5 Release proﬁle of theophylline from formulations TN4,
TN5, and TN6 compressed at 5 and 10 kN.
236 I. El-Bagory et al.tern of TN from this matrix tablet formulae was very clear
when the comparison was made between the all formulae using
the same compression force. On the other hand, when one for-
mula was subjected to different compression forces, the com-
parison will be of a narrow range, i.e., the in vitro release
curves of different compression forces were superimposing.
During the tablet compression cycle, when the load is ﬁrst
applied, the volume of the mass decreases because some of
the air between particles is displaced as the particles move clo-
ser together. This is the repacking phase (Khossravi, 1999).Table 4A Mathematical modeling and theophylline release kinetic
Korsmeyer–Peppas model Higuchi model
n# K (hn) r K (%h1/2) r
0.41 16.7 0.998 13.71 0.996
0.383 16.94 0.989 13.24 0.994
0.432 12.52 0.993 10.93 0.997
0.476 16.85 0.99 16.14 0.997
0.483 14.03 0.969 14.17 0.987
0.522 17.64 0.995 18.53 0.998
0.41 17.47 0.997 14.35 0.996
0.386 16.29 0.994 12.71 0.994
0.39 14.58 0.996 11.34 0.993
0.435 16.79 0.989 14.81 0.997
0.511 14.11 0.985 14.97 0.992
0.478 17.73 0.990 16.88 0.995This phase is limited by attainment of the closest possible
packing arrangement and/or the friction at the particle contact
points. After repacking, most materials then begin (or may
have already begun) to undergo elastic deformation and con-
tinue to do so until they reach their elastic limit. Beyond this
so-called yield stress, various components of the formulation
may undergo plastic and/or viscid-elastic deformation. Vol-
ume reduction may also cause particles to undergo brittle frac-
ture. The proportion of deformation attributed to one
mechanism or another depends on whether the material as a
whole is more ductile or more brittle (Steve and Antonios,
2005). Formulators must determine this during product devel-
opment and, if elastic recovery is too pronounced, consider
adding an adequate quantity of plastic ingredients to compen-
sate. These deformation mechanisms hold great signiﬁcance
when considering the compression and consolidation-related
aspects of the tabletting process. In most formulations, the
repacking phase of compression occurs only at the low end
of the applied load, and one or more of the other mechanisms
rapidly overtake it. But repacking remains as an important fac-
tor because, for a given applied peak load, the ﬁnal porosity
(voidage) of the tablet depends to some extent on the porosity
of the material at initial loading. Thus, since the dissolution
rate of many tabletted products is a function of the tablets
residual micro-porosity, variability in the initial voidage level
may be the root cause of inconsistent dissolution proﬁles
(Tadashi et al., 2006). In many products, the extent of repack-
ing depends on the compaction rate. Usually, the higher the
compaction rate, the less repacking that occurs. Reduced
repacking is another possible root cause of inconsistent disso-
lution proﬁles. If repacking is reduced, the dissolution rate
tends to increase.
3.3. Kinetic assessment of the in-vitro release
The correlation coefﬁcient (r), and the release exponent (n), of
ﬁtting the release data to zero, ﬁrst, Higuchi diffusion and
Peppas models for TN matrix tablets are listed in Tables 4A
and 4B in addition to Fig. 6. The higher correlation coefﬁcient
(r) values for Higuchi diffusion model obtained in most formu-
lae indicates a diffusion mechanism for TN release. The kinetic
data provide that the Higuchi diffusion model is the prominent
mechanism that controls the release of TN from the testedfrom tablets.
First order Zero order Formulation
K (h1) r Ko (%h
1) r
0.055 0.957 4.2 0.931 TN1
0.053 0.959 4.08 0.933 TN2
0.042 0.966 3.41 0.948 TN3
0.0699 0.975 5.06 0.952 TN4
0.0607 0.981 4.57 0.969 TN5
0.0858 0.985 5.85 0.960 TN6
0.059 0.962 4.42 0.935 TN1
0.05 0.954 3.89 0.929 TN2
0.043 0.943 3.44 0.920 TN3
0.062 0.974 4.63 0.950 TN4
0.0647 0.986 4.81 0.973 TN5
0.075 0.974 5.28 0.949 TN6
Table 4B Mathematical modeling and theophylline release kinetic from tablets compressed at 15 and 20 kN.
Korsmeyer–Peppas model Higuchi model First order Zero order Formulation
n# K (hn) r K (%h1/2) r K (h1) r Ko (%h
1) r
0.376 18.6 0.993 14.14 0.990 0.057 0.946 4.29 0.917 TN1
0.376 15.5 0.995 11.82 0.993 0.045 0.948 3.6 0.923 TN2
0.362 16.74 0.997 12.19 0.989 0.046 0.935 3.67 0.908 TN3
0.398 16.75 0.983 13.66 0.991 0.056 0.963 4.25 0.941 TN4
0.538 14.03 0.990 15.72 0.994 0.0689 0.989 5.06 0.975 TN5
0.434 18.22 0.993 15.81 0.995 0.0683 0.969 4.9 0.942 TN6
0.396 20.8 0.99 16.3 0.991 0.07 0.95 4.97 0.918 TN1
0.334 16.1 0.987 11.08 0.983 0.0417 0.926 3.32 0.9 TN2
0.397 16.9 0.988 13.66 0.995 0.0559 0.964 4.23 0.939 TN3
0.408 17.3 0.997 14.16 0.9966 0.058 0.961 4.35 0.934 TN4
0.534 14.55 0.9951 16.02 0.9965 0.07 0.988 5.13 0.972 TN5
0.444 17.5 0.9958 15.66 0.9979 0.067 0.975 4.89 0.949 TN6
Formulation and in vitro evaluation of theophylline matrix tablets prepared by direct compression: 237matrix tablet formulation even at different compression forces
(due to higher correlation coefﬁcient values). In addition, the
magnitude of the Higuchi diffusion rate constant (K) was
found to be dependent on the formulae composition (i.e. effect
of matrix forming polymer nature) and the compression force.
For example, increasing concentration of KL SR in the formu-
lae resulted in a reduction of the (K) value in the formulae
TN1–TN3 (based on higher weight ratio of KL SR). In con-
trast, the value of (K) was increased by the presence of higher
weight ratios of EC and CW tablet formulations; TN4–TN6.
This ﬁnding is true for all TN formulations compressed at 5,
10 and 15 kN. However, when these formulae were com-
pressed at 20 kN, the drug exhibited higher K values from for-
mulae TN1, TN5 and TN6 (16.3, 16.02 and 15.66% h1/2,
respectively).
4. Conclusion
The design of directly compressed matrix tablets for sustained
release properties should take into consideration the deforma-
tion mechanism of used polymers. In addition, the critical
parameters such as tabletting conditions, compression forces,10
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19
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Figure 6 Release constant (K) calculated from Higuchi diffusion
model for Theophylline matrix tablet formulations compressed at
different compression force 5, 10, 15 and 20 Kn.upper and lower punch compression forces, hardness, tensile
strength and friability will be affected according to the defor-
mation mechanism of such polymers.Acknowledgements
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